Keywords: guilford, posts, 8m, loss, 2nd, quarter, nasdaq-listed
Guilford posts $16.8M loss in 2nd quarter
Article | 19 August 2002
Nasdaq-listed Guilford Pharmaceuticals has posted a second-quarter 2002net loss of $16.8 million, or $0.57 per share, compared with $18.2 million and $0.67, respectively, during ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
